What is the cost per unit for Daxxify vs Jeuveau at wholesale?

Daxxify wholesale pricing ranges from $12–16 per unit, while Jeuveau is more aggressive at $8–11 per unit. For a 20-unit glabellar treatment, Daxxify costs roughly $240–400 at acquisition versus $160–220 for Jeuveau.

Is Daxxify more cost-effective than Jeuveau over a year?

Yes. Although Daxxify costs more per treatment, patients need only 2 treatments yearly versus 4 for Jeuveau. Over 12 months, Daxxify's per-month cost to patients ($67–100) is often lower than Jeuveau's ($83–133), even at higher per-treatment pricing.

Why was Daxxify approved for longer duration than other neuromodulators?

Daxxify uses a proprietary peptide-excipient complex formulation that extends duration without increasing units. The pivotal trial showed median 6-month duration with roughly 50% of patients maintaining visible improvement at the 6-month mark—a genuine clinical advantage backed by FDA clearance in September 2022.

Which neuromodulator should I stock if I want to compete on price?

Jeuveau is the budget option, with wholesale pricing at $8–11 per unit and retail pricing typically $250–400 per treatment. It's positioned for practices competing on cost or targeting first-time Botox patients, as it lacks a duration advantage over standard toxins.

Does Daxxify generate more revenue per patient visit than Jeuveau?

Yes. Daxxify patients require fewer appointments (2 per year vs. 4 for Jeuveau) but generate higher per-visit revenue and better retention due to reduced scheduling friction and fewer no-shows. This makes Daxxify better for practices prioritizing per-appointment profitability and patient convenience.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Injectables

Daxxify vs Jeuveau: Duration, Cost, and Clinical Positioning

Q: How long does Daxxify last compared to Jeuveau?

Daxxify lasts up to 6 months (median 6 months, with some patients reaching 6.5 months), while Jeuveau typically lasts 3–4 months, matching standard Botox and Dysport. Daxxify is the only FDA-cleared neuromodulator with this extended duration profile.

How the extended-duration toxin and the budget neuromodulator stack up on longevity, per-treatment economics, and market positioning.

By Evan at Inside MedSpa · Jun 26, 2026

1-YEAR MOVE

EOLS ▼15.6% ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
EOLS	Evolus	−15.6%
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Daxxify and Jeuveau occupy opposite ends of the neuromodulator spectrum: Daxxify is FDA-cleared for up to 6 months of effect, while Jeuveau typically lasts 3–4 months, matching standard Botox and Dysport duration. The real differentiation lies in per-treatment cost, patient retention, and how each fits into your revenue model.

Duration and Clinical Claims

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/daxxify-vs-jeuveau/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →